Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a

P Chedid1,2,3, T Boussetta1,2,3, P M-C Dang1,2,3

  • 1Inserm, U1149, CNRS-ERL8252, Centre de Recherche sur l'Inflammation (CRI), Paris, France.

Mucosal Immunology
|June 9, 2016
PubMed

Insights

Vasoactive intestinal peptide (VIP) inhibits reactive oxygen species (ROS) production by phagocytes, specifically targeting the NOX2 enzyme. This peptide demonstrates anti-inflammatory effects by blocking key signaling pathways, suggesting its potential as a novel therapeutic agent.

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Reactive oxygen species (ROS) are crucial for microbial clearance via phagocyte NADPH oxidase (NOX2) but can cause tissue damage when overproduced.
  • NOX2 is a complex enzyme involving membrane-bound cytochrome b588 and cytosolic components like p47phox, p67phox, p40phox, and rac1/2.

Purpose of the Study:

  • To investigate the effect of vasoactive intestinal peptide (VIP) on ROS production by NOX2 in human phagocytes.
  • To elucidate the signaling pathways and receptors involved in VIP's modulation of NOX2 activity.

Main Methods:

  • Primary human phagocytes were used to assess ROS production in response to bacterial peptide fMLF.
  • VIP's effects were analyzed using specific agonists and antagonists for VPAC1 receptors.
  • Western blotting was employed to examine the phosphorylation status of ERK1/2, p38MAPK, and p47phox.
  • An in vivo rat model of carrageenan-induced inflammation was used to evaluate VIP's anti-inflammatory properties.

Main Results:

  • VIP inhibited fMLF-induced ROS production in monocytes but not neutrophils.
  • VIP's inhibitory action was mediated via the VPAC1 receptor.
  • VIP suppressed the phosphorylation of ERK1/2, p38MAPK, and p47phox (Ser345).
  • VIP demonstrated significant anti-inflammatory effects in a rat model of acute inflammation.

Conclusions:

  • VIP acts as a natural anti-inflammatory agent, particularly within the mucosal system.
  • VIP inhibits NOX2 activation through the "MAPK-p47phox phosphorylation-NOX2 activation" pathway.
  • VIP and its analogs hold potential as novel therapeutic molecules for inflammatory conditions.

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.2K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
909
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.7K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.5K